The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
LLMC 2020 | Oral therapies in the future of AML treatment
Sangmin Lee, MD, Weill Cornell Medical College, New York City, NY, discusses the future of acute myeloid leukemia (AML) treatment, highlighting the approval of oral azacitidine as a maintenance therapy for patients undergoing induction chemotherapy who are not eligible for curative therapy as a result of the Phase III QUAZAR AML-001 trial (NCT01757535). Dr Lee also discusses how future research will focus on developing oral hypomethylating agents to be used in combination with oral venetoclax. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
Disclosures
Consultancy: AstraZeneca, BMS, Jazz, Roche Diagnostics
DSMB membership: Helsinn
